Pub Date : 2025-11-08DOI: 10.1001/jamacardio.2025.4548
Vencel Juhasz, Zsofia D. Drobni, Thiago Quinaglia, Hannah K. Gilman, Jan M. Brendel, Giselle Alexandra Suero-Abreu, Azin Ghamari, Julius C. Heemelaar, Donna S. Neuberg, Yuchi Han, Bonnie Ky, Raymond Y. Kwong, James L. Januzzi, Aarti Asnani, Negareh Mousavi, Robert A. Redd, Michael Jerosch-Herold, Marielle Scherrer-Crosbie, Tomas G. Neilan
Importance Anthracyclines, which are key to many chemotherapeutic protocols, have been associated with increased vascular stiffness, a major factor associated with cardiovascular morbidity and mortality. There is no evidence-based intervention to prevent anthracycline-associated vascular dysfunction. Objective To investigate whether atorvastatin pretreatment is associated with attenuation of the anthracycline-induced increase in aortic stiffness. Design, Setting, and Participants This study is a secondary analysis of a double-blind, randomized clinical trial (Statins to Prevent the Cardiotoxicity From Anthracyclines [STOP-CA]). Enrollment occurred between January 25, 2017, and September 10, 2021, with the last follow-up on October 10, 2022. Primary analyses were reported on August 8, 2023. STOP-CA was a multicenter trial across 9 academic centers in the US and Canada. Participants were patients with newly diagnosed lymphoma scheduled to undergo anthracycline-based chemotherapy with no clinical indication for a statin. Intervention Atorvastatin (40 mg, once daily) or placebo for 12 months. Main Outcomes and Measures This subanalysis of the STOP-CA trial includes post hoc end points with cardiac magnetic resonance imaging–derived aortic arch pulse wave velocity (PWV) and aortic distensibility (AD). An intention-to-treat approach was applied. The proportions of participants with a 1 SD or more increase in PWV and a 1 SD or more decrease in ascending aortic distensibility (AAD) were calculated in each group over 12 months. An increase in PWV of 0.15 m per second or more, a previously defined annual rate in individuals of similar age, was also assessed as a secondary end point. Results Of the 300 participants (150 randomized to atorvastatin and 150 randomized to placebo), 152 (mean [SD] age, 51 [17] years; 72 female [47%]; 82 treated with atorvastatin) had paired PWV data, and 168 had paired AD data. The PWV values remained similar in the atorvastatin group (mean [SD], 6.5 [1.9] vs 6.5 [2.0] m per second) but increased in the placebo group (5.7 [1.8] vs 6.8 [2.0] m per second) over 12 months. A 1 SD or more increase (0.8 m per second) in PWV was observed among 4 of 82 patients (5%) with atorvastatin and 35 of 70 patients (50%) with placebo (odds ratio, 0.05; 95% CI, 0.02 to 0.16; <jats:italic>P</jats:italic> &lt; .001) at 12 months. A 1 SD or more decrease (1.8 × 10 <jats:sup>−3</jats:sup> mm Hg <jats:sup>−1</jats:sup> ) in AAD was observed among 6 of 88 patients (7%) with atorvastatin and in 14 of 80 patients (18%) with placebo. A 1 SD or more increase in PWV was associated with a mean left ventricular ejection fraction decline of 2.70% (95% CI, −4.65% to −0.81%; <jats:italic>P</jats:italic> = .006). Conclusions and Relevance Pretreatment with atorvastatin was associated with preservation of vascular function among patients with lymphoma undergoing anthracycline-based chemotherapy. Trial Registration ClinicalTrials.gov Identifier: <jats:ext-l
{"title":"Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy","authors":"Vencel Juhasz, Zsofia D. Drobni, Thiago Quinaglia, Hannah K. Gilman, Jan M. Brendel, Giselle Alexandra Suero-Abreu, Azin Ghamari, Julius C. Heemelaar, Donna S. Neuberg, Yuchi Han, Bonnie Ky, Raymond Y. Kwong, James L. Januzzi, Aarti Asnani, Negareh Mousavi, Robert A. Redd, Michael Jerosch-Herold, Marielle Scherrer-Crosbie, Tomas G. Neilan","doi":"10.1001/jamacardio.2025.4548","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.4548","url":null,"abstract":"Importance Anthracyclines, which are key to many chemotherapeutic protocols, have been associated with increased vascular stiffness, a major factor associated with cardiovascular morbidity and mortality. There is no evidence-based intervention to prevent anthracycline-associated vascular dysfunction. Objective To investigate whether atorvastatin pretreatment is associated with attenuation of the anthracycline-induced increase in aortic stiffness. Design, Setting, and Participants This study is a secondary analysis of a double-blind, randomized clinical trial (Statins to Prevent the Cardiotoxicity From Anthracyclines [STOP-CA]). Enrollment occurred between January 25, 2017, and September 10, 2021, with the last follow-up on October 10, 2022. Primary analyses were reported on August 8, 2023. STOP-CA was a multicenter trial across 9 academic centers in the US and Canada. Participants were patients with newly diagnosed lymphoma scheduled to undergo anthracycline-based chemotherapy with no clinical indication for a statin. Intervention Atorvastatin (40 mg, once daily) or placebo for 12 months. Main Outcomes and Measures This subanalysis of the STOP-CA trial includes post hoc end points with cardiac magnetic resonance imaging–derived aortic arch pulse wave velocity (PWV) and aortic distensibility (AD). An intention-to-treat approach was applied. The proportions of participants with a 1 SD or more increase in PWV and a 1 SD or more decrease in ascending aortic distensibility (AAD) were calculated in each group over 12 months. An increase in PWV of 0.15 m per second or more, a previously defined annual rate in individuals of similar age, was also assessed as a secondary end point. Results Of the 300 participants (150 randomized to atorvastatin and 150 randomized to placebo), 152 (mean [SD] age, 51 [17] years; 72 female [47%]; 82 treated with atorvastatin) had paired PWV data, and 168 had paired AD data. The PWV values remained similar in the atorvastatin group (mean [SD], 6.5 [1.9] vs 6.5 [2.0] m per second) but increased in the placebo group (5.7 [1.8] vs 6.8 [2.0] m per second) over 12 months. A 1 SD or more increase (0.8 m per second) in PWV was observed among 4 of 82 patients (5%) with atorvastatin and 35 of 70 patients (50%) with placebo (odds ratio, 0.05; 95% CI, 0.02 to 0.16; <jats:italic>P</jats:italic> &amp;lt; .001) at 12 months. A 1 SD or more decrease (1.8 × 10 <jats:sup>−3</jats:sup> mm Hg <jats:sup>−1</jats:sup> ) in AAD was observed among 6 of 88 patients (7%) with atorvastatin and in 14 of 80 patients (18%) with placebo. A 1 SD or more increase in PWV was associated with a mean left ventricular ejection fraction decline of 2.70% (95% CI, −4.65% to −0.81%; <jats:italic>P</jats:italic> = .006). Conclusions and Relevance Pretreatment with atorvastatin was associated with preservation of vascular function among patients with lymphoma undergoing anthracycline-based chemotherapy. Trial Registration ClinicalTrials.gov Identifier: <jats:ext-l","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"82 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-08DOI: 10.1001/jamacardio.2025.4477
Kevin M Alexander,Margot K Davis,Olakunle Akinboboye,John Berk,Kunal Bhatt,Francesco Cappelli,Sarah A M Cuddy,Marianna Fontana,Pablo Garcia-Pavia,Julian D Gillmore,Jan M Griffin,Justin L Grodin,Daniel P Judge,Michel G Khouri,Kaitlyn Lam,Ahmad Masri,Mathew S Maurer,Laura Obici,Frederick L Ruberg,Nitasha Sarswat,Keyur Shah,Prem Soman,Lily Stern,Richard Wright,Kuangnan Xiong,Xiaofan Cao,Ted Lystig,Jean-François Tamby,Adam Castaño,Leonid Katz,Uma Sinha,Jonathan C Fox,Scott D Solomon,Martha Grogan
ImportanceTransthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease caused by misfolded transthyretin (TTR), occurs as wild-type (ATTRwt-CM) or variant (ATTRv-CM) forms. p.Val142Ile is the most common variant in the US, linked to rapid progression and increased mortality. Acoramidis achieves near-complete (≥90%) TTR stabilization and showed clinical benefit in the 30-month ATTRibute-CM trial and through month 42 in the ongoing open-label extension (OLE).ObjectiveTo evaluate the efficacy of acoramidis in ATTRwt-CM, ATTRv-CM, and variant subgroups (p.Val142Ile and non-p.Val142Ile).Design, Setting, and ParticipantsThis international, multicenter, phase 3, randomized placebo-controlled study took place from April 2019 to May 2023 with ongoing OLE (month 42). ATTRibute-CM enrolled 632 participants with ATTR-CM; 611 of 632 were included in the modified intention-to-treat (mITT) population. There were 380 participants who continued into the OLE. These data were analyzed from January 2025 to July 2025.InterventionsOral acoramidis, 712 mg, or placebo twice daily for 30 months, followed by 12 months of open-label treatment.Main Outcomes and MeasuresAll-cause mortality (ACM), cardiovascular-related hospitalizations (CVH), serum TTR, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire Overall Summary score, and N-terminal pro B-type natriuretic peptide in participants with ATTRwt-CM and ATTRv-CM. Post-hoc analyses were conducted in variant subgroups, including p.Val142Ile.ResultsOverall, 552 participants with wild-type ATTR-CM (mean [SD] age, 78 [6.3] years; 92.0% male and 8.0% female) and 59 participants with variant ATTR-CM (mean [SD] age, 73 [7.7] years; 77.3% male and 22.7% female) were randomized (mITT population), including 35 with p.Val142Ile. Consistent efficacy was observed in wild-type and variant subgroups for ACM/CVH through month 30 and ACM through month 42. At month 30, acoramidis reduced the risk of ACM/first CVH vs placebo by 31% in ATTRwt-CM (hazard ratio [HR], 0.69; 95% CI, 0.52-0.90; P = .007) and by 59% in ATTRv-CM (HR, 0.41; 95% CI, 0.21-0.81; P = .01). ACM was reduced through month 42 with HRs of 0.70 (95% CI, 0.50-0.98; P = .04) and 0.41 (95% CI, 0.19-0.93; P = .03) in the ATTRwt-CM and ATTRv-CM groups, respectively. Consistent treatment benefit was observed in participants with ATTRwt-CM and ATTRv-CM for secondary end points. Within variant subgroups (p.Val142Ile vs non-p.Val142Ile), consistent treatment benefits were observed for ACM/CVH through month 30 and ACM through month 42.Conclusions and RelevanceThe beneficial effect of acoramidis was observed consistently in ATTRwt-CM and ATTRv-CM groups. These hypothesis-generating results indicate that further studies are warranted to better characterize the therapeutic benefit of acoramidis in variant subgroups.Trial RegistrationClinicalTrials.gov Identifiers: NCT03860935; NCT04988386.
{"title":"Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.","authors":"Kevin M Alexander,Margot K Davis,Olakunle Akinboboye,John Berk,Kunal Bhatt,Francesco Cappelli,Sarah A M Cuddy,Marianna Fontana,Pablo Garcia-Pavia,Julian D Gillmore,Jan M Griffin,Justin L Grodin,Daniel P Judge,Michel G Khouri,Kaitlyn Lam,Ahmad Masri,Mathew S Maurer,Laura Obici,Frederick L Ruberg,Nitasha Sarswat,Keyur Shah,Prem Soman,Lily Stern,Richard Wright,Kuangnan Xiong,Xiaofan Cao,Ted Lystig,Jean-François Tamby,Adam Castaño,Leonid Katz,Uma Sinha,Jonathan C Fox,Scott D Solomon,Martha Grogan","doi":"10.1001/jamacardio.2025.4477","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.4477","url":null,"abstract":"ImportanceTransthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease caused by misfolded transthyretin (TTR), occurs as wild-type (ATTRwt-CM) or variant (ATTRv-CM) forms. p.Val142Ile is the most common variant in the US, linked to rapid progression and increased mortality. Acoramidis achieves near-complete (≥90%) TTR stabilization and showed clinical benefit in the 30-month ATTRibute-CM trial and through month 42 in the ongoing open-label extension (OLE).ObjectiveTo evaluate the efficacy of acoramidis in ATTRwt-CM, ATTRv-CM, and variant subgroups (p.Val142Ile and non-p.Val142Ile).Design, Setting, and ParticipantsThis international, multicenter, phase 3, randomized placebo-controlled study took place from April 2019 to May 2023 with ongoing OLE (month 42). ATTRibute-CM enrolled 632 participants with ATTR-CM; 611 of 632 were included in the modified intention-to-treat (mITT) population. There were 380 participants who continued into the OLE. These data were analyzed from January 2025 to July 2025.InterventionsOral acoramidis, 712 mg, or placebo twice daily for 30 months, followed by 12 months of open-label treatment.Main Outcomes and MeasuresAll-cause mortality (ACM), cardiovascular-related hospitalizations (CVH), serum TTR, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire Overall Summary score, and N-terminal pro B-type natriuretic peptide in participants with ATTRwt-CM and ATTRv-CM. Post-hoc analyses were conducted in variant subgroups, including p.Val142Ile.ResultsOverall, 552 participants with wild-type ATTR-CM (mean [SD] age, 78 [6.3] years; 92.0% male and 8.0% female) and 59 participants with variant ATTR-CM (mean [SD] age, 73 [7.7] years; 77.3% male and 22.7% female) were randomized (mITT population), including 35 with p.Val142Ile. Consistent efficacy was observed in wild-type and variant subgroups for ACM/CVH through month 30 and ACM through month 42. At month 30, acoramidis reduced the risk of ACM/first CVH vs placebo by 31% in ATTRwt-CM (hazard ratio [HR], 0.69; 95% CI, 0.52-0.90; P = .007) and by 59% in ATTRv-CM (HR, 0.41; 95% CI, 0.21-0.81; P = .01). ACM was reduced through month 42 with HRs of 0.70 (95% CI, 0.50-0.98; P = .04) and 0.41 (95% CI, 0.19-0.93; P = .03) in the ATTRwt-CM and ATTRv-CM groups, respectively. Consistent treatment benefit was observed in participants with ATTRwt-CM and ATTRv-CM for secondary end points. Within variant subgroups (p.Val142Ile vs non-p.Val142Ile), consistent treatment benefits were observed for ACM/CVH through month 30 and ACM through month 42.Conclusions and RelevanceThe beneficial effect of acoramidis was observed consistently in ATTRwt-CM and ATTRv-CM groups. These hypothesis-generating results indicate that further studies are warranted to better characterize the therapeutic benefit of acoramidis in variant subgroups.Trial RegistrationClinicalTrials.gov Identifiers: NCT03860935; NCT04988386.","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"39 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-08DOI: 10.1001/jamacardio.2025.4581
Jingyi Gong, Muthiah Vaduganathan, Rishi K. Wadhera
Importance Chronic kidney disease (CKD) is common and often coexists with cardiometabolic risk factors and cardiovascular disease (CVD). Objectives To evaluate CKD prevalence and awareness among US adults overall and in those with cardiometabolic risk factors or CVD. Design, Setting, and Participants This serial cross-sectional study was conducted among US adults aged 20 years or older participating in the National Health and Nutrition Examination Survey between 2011 and March 2020. Main Outcomes and Measures The primary outcomes were prevalence of CKD, defined as estimated glomerular filtration rate less than 60 mL/min/1.73 m 2 or urine albumin to creatinine ratio of 30 mg/g or greater, and awareness, based on self-report of a “yes” response to the question “Ever told you had weak/failing kidneys?” among all US adults and those with cardiometabolic conditions (hypertension, diabetes, hyperlipidemia, obesity) or CVD. Survey-weighted logistic regression models were also fit to determine temporal changes in prevalence over the study period. Results This cross-sectional study included 24 646 adults (weighted mean age, 49 years; 48.4% female), including 20 224 adults with cardiometabolic risk factors or CVD. The overall prevalence of CKD among US adults was 14.6% (95% CI, 14.0%-15.3%), and only 12.3% (95% CI, 11.1%-13.5%) were aware of “weak/failing” kidneys. Among adults with cardiometabolic risk factors or CVD, CKD prevalence was 16.7% (95% CI, 16.0%-17.4%). Awareness of “weak/failing” kidneys was low in this population—only 13.2% (95% CI, 11.9%-14.4%) were aware of their diagnosis over the study period, and the largest awareness gaps occurred among those aged 20 to 64 years, women, and Hispanic adults. Although awareness among adults with CKD and cardiometabolic conditions increased modestly, from 11.5% (95% CI, 8.5%-14.5%) in 2011-2012 to 15.1% (95% CI, 13.1%-17.2%) in 2017 through March 2020 ( P = .02), these gains were concentrated among older adults aged 65 years or older (10.8%; 95% CI, 6.9%-14.6% to 17.7%; 95% CI, 14.2%-21.3%), men (9.7%; 95% CI, 5.6%-13.8% to 18.4%; 95% CI, 15.5%-21.4%), and non-Hispanic White adults (10.8%; 95% CI, 6.1%-15.5% to 16.3%; 95% CI, 13.4%-19.2%). No significant improvements in awareness were observed among younger adults aged 20 to 64 years, women, or Black and Hispanic adults. Conclusions and Relevance In this nationally representative study, CKD affected 1 in 6 US adults with cardiometabolic conditions, and only a minority of respondents were aware of “weak/failing” kidneys. These findings underscore a significant opportunity to promote awareness and optimal management of CKD.
{"title":"Chronic Kidney Disease Prevalence and Awareness Among US Adults","authors":"Jingyi Gong, Muthiah Vaduganathan, Rishi K. Wadhera","doi":"10.1001/jamacardio.2025.4581","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.4581","url":null,"abstract":"Importance Chronic kidney disease (CKD) is common and often coexists with cardiometabolic risk factors and cardiovascular disease (CVD). Objectives To evaluate CKD prevalence and awareness among US adults overall and in those with cardiometabolic risk factors or CVD. Design, Setting, and Participants This serial cross-sectional study was conducted among US adults aged 20 years or older participating in the National Health and Nutrition Examination Survey between 2011 and March 2020. Main Outcomes and Measures The primary outcomes were prevalence of CKD, defined as estimated glomerular filtration rate less than 60 mL/min/1.73 m <jats:sup>2</jats:sup> or urine albumin to creatinine ratio of 30 mg/g or greater, and awareness, based on self-report of a “yes” response to the question “Ever told you had weak/failing kidneys?” among all US adults and those with cardiometabolic conditions (hypertension, diabetes, hyperlipidemia, obesity) or CVD. Survey-weighted logistic regression models were also fit to determine temporal changes in prevalence over the study period. Results This cross-sectional study included 24 646 adults (weighted mean age, 49 years; 48.4% female), including 20 224 adults with cardiometabolic risk factors or CVD. The overall prevalence of CKD among US adults was 14.6% (95% CI, 14.0%-15.3%), and only 12.3% (95% CI, 11.1%-13.5%) were aware of “weak/failing” kidneys. Among adults with cardiometabolic risk factors or CVD, CKD prevalence was 16.7% (95% CI, 16.0%-17.4%). Awareness of “weak/failing” kidneys was low in this population—only 13.2% (95% CI, 11.9%-14.4%) were aware of their diagnosis over the study period, and the largest awareness gaps occurred among those aged 20 to 64 years, women, and Hispanic adults. Although awareness among adults with CKD and cardiometabolic conditions increased modestly, from 11.5% (95% CI, 8.5%-14.5%) in 2011-2012 to 15.1% (95% CI, 13.1%-17.2%) in 2017 through March 2020 ( <jats:italic toggle=\"yes\">P</jats:italic> = .02), these gains were concentrated among older adults aged 65 years or older (10.8%; 95% CI, 6.9%-14.6% to 17.7%; 95% CI, 14.2%-21.3%), men (9.7%; 95% CI, 5.6%-13.8% to 18.4%; 95% CI, 15.5%-21.4%), and non-Hispanic White adults (10.8%; 95% CI, 6.1%-15.5% to 16.3%; 95% CI, 13.4%-19.2%). No significant improvements in awareness were observed among younger adults aged 20 to 64 years, women, or Black and Hispanic adults. Conclusions and Relevance In this nationally representative study, CKD affected 1 in 6 US adults with cardiometabolic conditions, and only a minority of respondents were aware of “weak/failing” kidneys. These findings underscore a significant opportunity to promote awareness and optimal management of CKD.","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"161 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-05DOI: 10.1001/jamacardio.2025.4105
Andre Zimerman,J Antonio G López,Robert S Rosenson,Daniel Gaudet,Seth J Baum,Jeong-Gun Park,Jingying Wang,Huei Wang,You Wu,Helina Kassahun,Marc S Sabatine,Michelle L O'Donoghue
{"title":"Small-Interfering RNA Olpasiran and Apolipoprotein B Particles.","authors":"Andre Zimerman,J Antonio G López,Robert S Rosenson,Daniel Gaudet,Seth J Baum,Jeong-Gun Park,Jingying Wang,Huei Wang,You Wu,Helina Kassahun,Marc S Sabatine,Michelle L O'Donoghue","doi":"10.1001/jamacardio.2025.4105","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.4105","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"28 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145440735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-05DOI: 10.1001/jamacardio.2025.4079
Heather M Prendergast,Spyros Kitsiou,Barry Carter
{"title":"Concerns About Diagnosing Hypertension in the Emergency Department-Reply.","authors":"Heather M Prendergast,Spyros Kitsiou,Barry Carter","doi":"10.1001/jamacardio.2025.4079","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.4079","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"1 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145440736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1001/jamacardio.2025.3109
Kosuke Inoue, Sérgio R R Decker, Ivy Shi, Lichen Liang, Yang Song, Sadiya S Khan, Dhruv S Kazi
{"title":"Discontinuation of Semaglutide Among Older Adults With Diabetes in the US and Japan.","authors":"Kosuke Inoue, Sérgio R R Decker, Ivy Shi, Lichen Liang, Yang Song, Sadiya S Khan, Dhruv S Kazi","doi":"10.1001/jamacardio.2025.3109","DOIUrl":"10.1001/jamacardio.2025.3109","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":" ","pages":"1222-1224"},"PeriodicalIF":14.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12461593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1001/jamacardio.2025.3469
Domingo A Pascual-Figal, Jose J Fuster
{"title":"Clonal Hematopoiesis-Fuel to Inflame the Heart.","authors":"Domingo A Pascual-Figal, Jose J Fuster","doi":"10.1001/jamacardio.2025.3469","DOIUrl":"10.1001/jamacardio.2025.3469","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":" ","pages":"1083-1084"},"PeriodicalIF":14.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：